Introduction
Little is known about the genetic determinants of essential hypertension in humans, despite extensive investigations in animal models of high blood pressure and significant advances in the genetics of rare mendelian forms of hypertension (Lifton et al. 2001) . The combination of complex causation and etiological heterogeneity generates a unique challenge in the genetics of common human disorders. Genetic linkage and association studies in two major ethnic groups suggest a role for angiotensinogen (AGT) in human essential hypertension (Hata et al. 1994; Jeunemaitre et al. 1992) . AGT is the hormone precursor of angiotensin II, which affects both vascular structure and sodium homeostasis.
The association observed between both plasma AGT and hypertension and a molecular variant encoding a threonine instead of a methionine at residue 235, denoted T235, could either be causal or could serve as a marker for an unknown causal factor in the gene. Recent data reveal that, with few exceptions, genes carrying allele T235 exhibit an adenine six residues upstream of the initiation site of transcription, denoted A(-6), and M235 alleles have a guanine at this site, or G(-6) . Binding studies and transactivation experiments in cultured human cells revealed that this polymorphism in the proximal promoter of AGT affects specific interactions with nuclear proteins and leads to significant differences in promoter activity in vitro . By establishing a direct causal link between AGT copy number and both plasma AGT and blood pressure, gene titration experiments in transgenic mice have provided direct proof that a modest but sustained increase in AGT expression can lead to chronic elevation of arterial pressure (Kim et al. 1995) .
Given these observations, our working hypothesis is that molecular variation in the proximal promoter of AGT can impart differences in the regulatory response of the gene to changes in dietary sodium. The actual molecular mechanism, the relevant tissue site, and the physiological relationship of this genetic variation to blood pressure regulation remain to be characterized. The ultimate proof of a causal link between genetic variation and physiological change will have to rest on gene manipulation in experimental animals.
An initial step in this direction consists of identifying critical elements controlling AGT transcription in both human and mouse. Previous work with the human promoter has yielded intriguing results. A minimum promoter spanning nucleotides Ϫ32 to ϩ44 and including the TATA box appeared as active as the Ϫ1200 to ϩ44 segment (Fukamizu et al. 1990 ). In contrast, a promoter segment spanning nucleotides Ϫ32 to ϩ22 appeared inactive . Specific elements were identified on either side of the TATA box, initially without clue as to the actual transacting factors involved (Tamura et al. 1993 . Alignment of the human and mouse core promoters reveal conserved as well as nonconserved sequence segments, indicating the need for a formal comparative study of these two promoters. The following work documents the absolute requirement for functional interactions between Sp1 and TATA-binding protein in the initiation of transcription of AGT in the mouse, whereas additional alternate initiation pathways may exist in humans.
Methods

Cell culture
Mouse and human hepatoma cells (Hepa1-6 and HepG2) were maintained in DMEM containing 10% fetal bovine serum, 5 mM hydroxyethylpiperazine ethanesulfonic acid (HEPES), 100 IU/ml penicillin and 100 µg/ml streptomycin. The cells were kept in 5% CO 2 /95% air at 37°C. The conditionally immortalized murine cell line of proximal tubule epithelium, tsMPT, was maintained as described previously (Loghman-Adham et al. 1997 ).
Preparation of nuclear extracts
Nuclear extracts from Hepa1-6 cells, tsMPT cells, and HepG2 cells were prepared using modifications of the procedure of Dignam (Dignam et al. 1983 ). Final protein concentrations were between 2 and 5 mg/ml.
Electrophoretic mobility shift assay (EMSA)
Synthetic double-stranded AGT promoter sequences (Table 1) were phosphorylated at both ends using T4 polynucleotide kinase and (γ-32 P) ATP (NEN-Life Science, Boston, MA, USA). Nuclear extracts or purified proteins (Promega, Madison, WI, USA) were preincubated for 15 min on ice in a 20-µl reaction mixture containing 1.5 µg poly(dI-dC) (Amersham Pharmacia Biotech, New Jersey, NY, USA), 10% glycerol, 20 mM HEPES (pH 7.9), 50 mM KCl, 0.5 mM dithiothreitol (DTT), 0.2 mM ethylenediaminetetra acetate (EDTA), and 6.25 mM MgCl 2 in the presence or absence of 50-or 100-fold molar excess of specific or nonspecific double-stranded competitor DNA or specific or control antisera. Reactions with purified Sp1 or Sp3 contained 0.01% Tween-20 to prevent protein aggregation. A 200-fmol aliquot of 32 P-labeled double-stranded oligonucleotide probe was added, and the reaction was continued on ice for 15 min. The reactions were loaded onto 5.5% nondenaturing polyacrylamide gels in 0.5ϫ TBE (90 mM Tris-HCl at pH 8.0, 89 mM boric acid, 2 mM EDTA) and electrophoresed at 200 V for 2 h at room temperature. Antibodies against Sp1, Sp3, GATA-1, GATA-2, NF-1, AP-1, AP-2, and control-IgG, as well as purified oligonucleotides containing the consensus binding sites for Sp1, AP-2, NF-1, Oct-1, C/EBP, CRE, were obtained from Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA.
Plasmid construction
Mouse AGT promoter fragments were generated by polymerase chain reaction (PCR) using a genomic clone as template, primers with overhanging restriction sites (5Ј KpnI and 3Ј HindIII; Table 1 ), and Pfu-polymerase to minimize misincorporation. PCR fragments were digested with KpnI and HindIII and subcloned into KpnI-and HindIIIdigested pGL3-Basic, also double digested with KpnI and HindIII. The integrity of the promoter sequences was verified by DNA sequencing. All plasmids used for transfection experiments were isolated from the DM-1 Escherchia coli strain (dam Ϫ /dcm Ϫ ) to exclude the possibility of differential methylation effects.
AGT promoter construct 2 (Ϫ61 to ϩ44) was used as a template to generate Sp1, TATA, and Sp1/TATA mutant constructs by oligonucleotide-directed PCR mutagenesis using sense primers with the mutations. Once the mutant AGT promoter fragments were obtained by PCR, they were double digested with KpnI and HindIII and ligated into double-digested pGL3-Basic.
Human AGT (hAGT) promoter fragments were also generated by PCR using a previously generated hAGT promoter construct as template, primers with overhanging restriction sites (5Ј KpnI and 3Ј HindIII; Table 1 ), and Pfupolymerase to minimize misincorporation. Mutant hAGT promoter constructs were created by oligonucleotidedirected PCR mutagenesis. Double-digested PCR products were cloned into KpnI-and HindIII-digested pGL3-Basic, as described for the murine AGT promoter constructs.
DNA transfection and reporter gene assays
Transfection experiments were performed using the Promega Tfx-system (Promega) and the pGL3-Basic reporter system (Promega) lacking eukaryotic promoter and enhancer sequences. PCR-generated AGT promoter sequences were cloned into pGL3-Basic using KpnI and HindIII sites of the multiple cloning site 5Ј of the fireflyluciferase reporter gene. pGL3-Control (Promega) with the SV40 promoter and enhancer sequence 5Ј of the fireflyluciferase reporter gene served as a positive control, and pGL3-Basic without any eukaryotic promoter and enhancer sequence served as a negative control. The pRL-SV40 plasmid (Promega) was cotransfected in all experiments. Coexpression of Renilla luciferase under the control of an SV40 promoter and enhancer was used to standardize transfection efficiency. Cells (Hepa1-6 or HepG2) were seeded in 12-well plates (6 ϫ 10 5 per well) coated with collagen type I 48 h prior to transfection. Optimal transfection results were achieved with 1.45 pmol of AGT promoter plasmid DNA per well, the Tfx-10 cationic lipid mixture at a 3 : 1 DNA : lipid ratio, and an incubation time of 2 h. pRL-SV40 (0.145 pmol per well) was used to standardize for transfection efficiency. At 24 h post-transfection, the cells were washed with phosphate-buffered saline and lysed in 100 µl passive lysis buffer (Promega). Firefly and Renilla luciferase reporter gene activities were measured using the Dual Luciferase Activity Assay kit (Promega) and a Turner TD20e luminometer (Promega). All transfections were performed in triplicate and repeated in three independent experiments with two independent plasmid DNA preparations. All transfection results are expressed as the ratio of firefly luciferase activity over Renilla luciferase activity. HepG2 cells were transfected using the cationic lipid mixture Tfx-20 (Promega).
DNA sequence analysis
The 5Ј promoter sequence of the mouse AGT gene (129/ SvEv) obtained from a genomic library screen cloned into pBluescript was used for sequencing. Sequencing was performed using ABI 377 automated sequencing and dyeterminator technology. Sequencing information was generated by "walking," using primers derived from the sequenced 5Ј promoter region. Sequence information was verified by sequencing sense and antisense strands.
Identification of putative promoter elements
Putative transcription factor response elements were identified using TransFact and TF algorithms (Heinemeyer et al. 1999 (Heinemeyer et al. , 1998 .
DNase I footprint analysis
Fragments of the AGT promoter (Ϫ100 to ϩ44) were generated by PCR using γ-32 P-labeled forward or reverse primers. After spin dialysis (Centricon-100) and concentration, the probes were incubated with 2 to 15 fpU (footprinting unit, fpU) of recombinant human Sp1 (Promega) in a 50-µl reaction volume containing 12 mM HEPES (pH 7.9) 5 mM CaCl 2 , 5 mM MgCl 2 , and 5 to 250 ng DNase I. The reaction was stopped by the addition of 100 µl stop solution (12 mM HEPES at pH 7.9, 0.6 M sodium acetate at pH 7, 0.5% sodiumdodecyl sulfate, 0.1 mM EDTA, and 20 µg of tRNA). The DNA was extracted twice with phenol-chloroform (1 : 1, vol/vol) and precipitated in 2.5 volume of 100% ethanol prior to electrophoresis on a 6% polyacrylamide/8 M urea sequencing gel. To accurately determine the positions of protected bases, we prepared G, A, C, T sequence reactions (Maxam and Gilbat 1980) and ran them as markers in parallel lanes.
Results
The Ϫ61 to ϩ44 promoter construct is sufficient to achieve promoter activity To identify the minimal promoter length necessary for AGT transcription, we transfected a series of staggered mouse AGT promoter constructs into the murine kidney proximal tubule cell line tsMPT (Loghman-Adham et al. 1997 ) and the murine hepatoma cell line Hepa1-6 (Fig. 1) . Both cell lines were previously shown to express angiotensinogen.
In both cell lines, a minimal promoter construct (Ϫ32 to ϩ44) with only the TATA box showed no promoter activity when compared with the promoterless control reporter gene. Promoter activity was obtained with a minimal promoter spanning Ϫ61 to ϩ44. Further 5Ј extension resulted in a reduction of reporter gene activity. In tsMPT cells, promoter activity dropped to background levels, whereas in Hepa1-6 cells, AGT promoter activity was reduced by more than 70%. In contrast to the region between Ϫ32 and Ϫ61, several elements have been identified in the region between Ϫ91 and Ϫ61, including an AGE2 element (Tamura et al. 1993 , a SOAP (suppression or activation protein) binding site (Brasier et al. 1989) , and an Sp1 binding site (Congiu et al. 1992) . AGT promoter activity increased again with construct 4 (Ϫ412 to ϩ44, Fig. 1 ) to levels close to those observed with construct 2. In summary, these results confirm previous observations that a truncated AGT (Ϫ412) promoter is sufficient to achieve maximal promoter activity (Brasier et al. 1989) . These results also demonstrate that a minipromoter ranging from Ϫ61 to ϩ44 is sufficient for AGT promoter activity in tsMPT and Hepa1-6 cells in vitro.
To identify putative transcription factor binding sites within the region between Ϫ61 and the TATA-box, we used computer-aided sequence homology search algorithms and found several potential candidate response elements: GATA (Ϫ56 to Ϫ51), mycCF1 (Ϫ53 to Ϫ48), and two NF1 half sites (Ϫ50 to Ϫ47 and Ϫ44 to Ϫ41). Additionally, a potential intermediate affinity Sp1 site (Jones et al. 1986; Kriwacki et al. 1992 ) (Ϫ47 to Ϫ38) 5 bp adjacent to the TATA box was identified.
The promoter sequence immediately 5Ј to the TATA box is conserved between human, mouse, and rat AGT and contains an Sp1 binding site Sequence comparison between human and rodent proximal AGT promoter shows regions with a high degree of sequence homology interspersed with regions of low or no homology (Fig. 2) . In particular, a segment directly upstream of the TATA box, encompassing nucleotides Ϫ37 to Ϫ53, exhibits conservation between human and rodents. In the human sequence, we observed an intermediate affinity Sp1 binding site between Ϫ38 and Ϫ47. The same region of the mouse gene deviates by one (Ϫ46 C-to-T substitution), whereas the rat sequence shows two substitutions (Ϫ46 Cto-T substitution and Ϫ45 C-to-T substitution).
In vitro binding experiments demonstrated direct binding between Sp1 and the region between Ϫ61 and Ϫ32 (Fig.  3A) . EMSAs using an oligonucleotide probe spanning the region between Ϫ61 and Ϫ32 (6132) and Hepa1-6 nuclear extracts show the characteristic Sp1 binding pattern with Sp1 as the top band, Sp3 as the second band, and a nonspecific third band. Lanes 4 to 7 show various competition experiments. Competition with excess unlabeled 6132 resulted in complete loss of binding (lane 4); the same was 5). An oligonucleotide probe, including a mutation in the Sp1 binding domain of 6132, failed to compete in gelshift experiments (lane 6). Competition was also observed with a probe with a mutation in the putative GATA motif (mGATA, lane 7). Preincubation with anti-Sp1 antibodies resulted in the formation of a specific high-molecularweight complex (lane 8), which was not detected when only control IgG was used (lane 1). Identical patterns were observed when tsMPT nuclear extracts were used (data not shown).
The same binding patterns were observed when nuclear extracts prepared from the human hepatoma cell line HepG2 were used (Fig. 3B) .
Recombinant human Sp1 binds to the mouse Sp1 binding site between Ϫ51 and Ϫ34 Because the Sp1 element identified is in very close proximity to the TATA box, we investigated the region of Sp1-DNA contact more thoroughly by DNase I protection experiments. Protection studies using recombinant human Sp1 showed a protected region from Ϫ34 to Ϫ51 (Fig. 4) , suggesting no overlap with the TATA box.
The TATA box and the adjacent Sp1 site are necessary but not sufficient for murine AGT transcription
To demonstrate the functional significance of the Sp1 binding site immediately 5Ј of the TATA box and to determine whether the Sp1 binding site would be sufficient to initiate transcription, we generated a series of mutant AGT promoter constructs, with mutations in 1) the Sp1 binding site, 2) the TATA box, and 3) both the Sp1 binding site and the TATA box. We performed transfection experiments in Hepa1-6 (Fig. 5A ) and tsMPT cells (data not shown), comparing reporter gene activities of the wild-type promoters (Ϫ32 to ϩ44 and Ϫ61 to ϩ44) to the promoterless control and the various mutant constructs. In both cell lines, a minimal promoter, including the TATA box, is not active compared with the promoterless control, indicating that the TATA box alone is not sufficient to initiate transcription of murine AGT gene in vitro. A mutation inactivating the TATA box (mTATA) resulted in complete loss of reporter gene activity and demonstrates the functional necessity of the TATA box for AGT transcription. The Sp1 site (Ϫ47 to ϩ38) is necessary but also not sufficient to induce AGT transcription. A mutation in the Sp1 element (mSp1) also resulted in the complete loss of reporter gene activity. Mutations in the Sp1 site and the TATA box (mTATAmSp1) also eliminated reporter gene activity. These results demonstrate that 1) a minimal AGT promoter construct including only the TATA box is not active, 2) within the context of a short AGT promoter, both the Sp1 binding site and the TATA box are necessary for AGT transcription, and 3) the Sp1 binding site is not sufficient to induce transcription of murine AGT in vitro.
A minimal human AGT promoter construct is active and mutations in the TATA box and Sp1 site do not cause complete transcriptional inactivation To assess whether the proximal promoters of mouse and human AGT require the same transacting factors, we tested a series of human promoter constructs, spanning the region from Ϫ70 to ϩ44, with mutations in 1) the Sp1 binding site, 2) the TATA box, 3) the Sp1 binding site and the TATA box, and 4) a minimal promoter construct spanning the region from Ϫ32 to ϩ44 (Fig. 5B) . In transfection experiments in the human hepatoma cell line HepG2, the promoter construct, including the Sp1 site, was more active than a minimal construct including only the TATA box (construct 1) and all other constructs tested. Mutational inactivation of the Sp1 site or the TATA box led to significant reduction of reporter gene activity, but did not result in complete inactivation of the promoter. In vitro binding studies and competition experiments demonstrated that all generated mutations abrogated binding in vitro (data not shown). All promoter constructs showed significantly more transcriptional activity when compared with the promoterless control. These results suggested that, in contrast to the mouse AGT promoter, a minimal human AGT promoter (Ϫ32 to ϩ44) remains functionally active in the absence of either or both of the Sp1 and TATA binding site. Fig. 2 . Comparison of the promoter sequences of human, mouse, and rat AGT. Sequences of the human, mouse, and rat AGT promoters are displayed from Ϫ53 to ϩ9. Consensus binding sites are boxed Fig. 3A,B . Sp1 binding to the murine and human AGT promoter in vitro. A Binding of Sp1 and Sp3 to the murine AGT promoter using Hepa1-6 nuclear extracts and an oligonucleotide probe spanning the promoter between Ϫ61 and Ϫ32 (6132) by electrophoretic gel mobility assay. B Binding of Sp1 to the human AGT promoter using HepG2 nuclear extracts and an oligonucleotide probe spanning the human promoter between Ϫ61 and Ϫ33 (6132) by electrophoretic gel mobility assay 1-4) . Increasing amounts (2 to 15 footprinting unit, fpU) of recombinant human Sp1 result in specific DNA protection (lanes 5-8) 
Discussion
A common AGT gene polymorphism (M235T) is associated with essential hypertension and preeclampsia (Hata et al. 1994; Jeunemaitre et al. 1992; Ward et al. 1993 ). This polymorphism was shown to be in very tight linkage disequilibrium with a mutation in the promoter of AGT, A(Ϫ6). Recent functional studies showed that the A(Ϫ6) promoter mutation leads to increased AGT T235 transcription in vitro relative to its G(Ϫ6) counterpart ).
Furthermore, elevated Ϫ6(A)/235T-AGT expression was shown in decidual spiral arteries of preeclamptic females (Morgan et al. 1997) , providing a direct link between increased tissue 235T expression and hypertensive disorders.
We have analyzed the proximal promoter of murine AGT to identify enhancer and promoter elements necessary for transcriptional activation of the murine AGT gene. Detailed information about basic, stimulated, or tissuespecific transcription of mouse AGT is necessary to establish the basis for future gene replacement experiments. The goal of such gene targeting studies is to assess in vivo effects of the AGT polymorphisms identified in human hypertensive subjects. Such studies require detailed understanding of the functional differences and similarities between the murine and human AGT promoters.
To establish the minimal length of a functional murine AGT promoter, we generated a series of staggered promoter constructs. Our results showed that a minimal murine AGT promoter (Ϫ32 to ϩ44) with only the TATA box is inactive. Promoter activity is achieved with a minipromoter A B extending 5Ј of the TATA box by 31 bp (Ϫ61 to ϩ44). Similar results were obtained for the mouse proximal tubule cell line (tsMPT) and the hepatoma cell line (Hepa1-6) ( Fig.  1) . Sequence analysis revealed several transcription factor consensus motifs within this region of transcriptional activation: GATA (Ϫ56 to Ϫ51), mycCF1 (Ϫ53 to Ϫ48), two NF1 half sites (Ϫ50 to Ϫ47 and Ϫ44 to Ϫ41), and an Sp1 site (Ϫ47 to Ϫ38) 5 bp adjacent to the TATA box. Using in vitro binding experiments, we identified Sp1 as the factor binding to this region (Figs. 3 and 4) .
The fact that a minimal murine AGT promoter (Ϫ32 to ϩ44) is inactive and that a minipromoter spanning the region from Ϫ61 to ϩ44 is sufficient for promoter activity led us to entertain the possibility that the Sp1 consensus binding site contributes to transcription initiation of mouse AGT (Fig. 5A) . We demonstrated that, within the context of a short AGT promoter, the Sp1 site (Ϫ47 to Ϫ38) is necessary but not sufficient for murine AGT transcription in vitro. Furthermore, mutational inactivation of the TATA box alone or in combination with the Sp1 binding site indicated that the Sp1 consensus motif and the TATA box are necessary but by themselves not sufficient for transcription of the murine AGT gene.
In contrast to the murine AGT promoter, a minimal human AGT promoter (Ϫ32 to ϩ44) is active, confirming previous observations (Fig. 5B) (Fukamizu et al. 1990 ). Similar to the mouse promoter, a human AGT promoter construct, including the Sp1 site (Ϫ70 to ϩ44), is more active when compared with a minimal promoter (Ϫ32 to ϩ44). Mutational inactivation of the Sp1 consensus motif, the TATA box, or combined inactivation of both sites resulted in reduced transcriptional activity but not in complete transcriptional inactivation of the AGT promoter in vitro. This observation suggests either cell line specific differences or the possibility of alternative, TATA boxindependent, mechanisms of initiation of transcription. The lack of transcriptional inactivation observed for the double mutant suggests yet another TATA box or Sp1-independent mechanism to initiate transcription of human AGT. A potential candidate for this function is the promoter region Fig. 5A,B . Analysis of the mouse AGT promoter by sitedirected mutagenesis and transfection analysis. A A minimal promoter (Ϫ32 to ϩ44) is inactive compared with a promoterless control (promoterless cont). 5Ј extension to Ϫ61 (Ϫ61 to ϩ44), including the Sp1 site, results in promoter activation (P Ͻ 0.0001). Mutational inactivation of the TATA box (mTATA), the Sp1 site (mSp1), or both sites (mSp1mTATA) results in loss of transcriptional activity. B Alternate transcription mechanisms may exist in transcriptional initiation of human AGT. The presence of the Sp1 site (Ϫ70 to ϩ44) results in promoter activation compared with a promoter with only the TATA box (Ϫ32 to ϩ44, P Ͻ 0.02), or a promoterless control (P Ͻ 0.01). Mutational inactivation of the TATA box (mTATA, P Ͻ 0.01), the Sp1 site (mSp1, P Ͻ 0.001), or both sites (mSp1mTATA, P Ͻ 0.05) does not result in complete loss of transcriptional activity reporter gene activity [Fluc/Rluc] reporter gene activity [Fluc/Rluc] A B between nucleotides Ϫ25 and ϩ1 (Yanai et al. 1997 ), a region without sequence homology in the mouse promoter. Functional studies by Yanai et al. (1997) have demonstrated that the binding activity has biological and immunological similarity to USF1, a helix-loop-helix nuclear factor (Sawadogo and Roeder 1985) , and mutational inactivation of this region leads to decreased promoter activity.
In promoters containing TATA elements, Sp1 interacts with the transcription initiation complex TFIID through specific binding to TATA-associated factors (Chen et al. 1994; Chiang and Roeder 1995; Ryu et al. 1999 ). Sp1 recruits and stabilizes basal factors through direct interaction with TAF 55 and TAF 110 (Chen et al. 1994; Chiang and Roeder 1995) . When Sp1 is present before and during formation of the preinitiation complex, it increases the amount of closed preinitiation complex assembled (Narayan and Wilson 2000) . When Sp1 is present only after the preinitiation complex is formed, it might stimulate transcription by modulation of protein-protein interactions and stimulation of promoter clearance (Narayan and Wilson 2000) . However, the precise molecular mechanisms by which Sp1 affects AGT gene transcription can only be investigated using in vitro reconstitution assays. In summary, this study demonstrates significant species-specific differences in AGT promoter function and emphasizes the difficulties in reconstituting the Ϫ6(A/G) promoter polymorphism in "genetically meaningful" transgenic mouse models. Because of species-specific differences of the Ϫ6 region, simple Ϫ6(A) substitution experiments may offer very limited functional information. This study also documents an instance where neither TATA nor Sp1 sites in the proximal promoter of a gene alone are sufficient to promote transcription.
